KromaTiD’s Dark Lab Files: A Blog
Advancements and Challenges in CAR T-Cell Therapy for Myeloid Malignancies
Great strides have been made in the treatment of B-cell malignancies with Chimeric antigen receptor (CAR) T-cell therapies. Efforts have been less successful when applying the technology to myeloid malignancies. Research published this year focusing on AML showcases the challenges.1 Myeloid malignancies, characterized by [...]
CB-011: A Gene-Edited CAR-T Therapy Against Multiple Myeloma
Multiple myeloma (MM) is a complex blood cancer affecting plasma cells. Patients can experience bone damage and fractures, kidney failure resulting from protein buildup, anemia and more frequent infections, among other symptoms. Given the disease's serious impacts to quality and length of life, scientists [...]
Genomic Insights into Cancer from the 100,000 Genomes Cancer Program
The 100,000 Genomes Cancer Program is a UK government research initiative aimed at integrating genomic data with clinical information to gain insights into the molecular basis of cancer. It involves the sequencing of genomes from 100,000 cancer patients, encompassing a diverse range of cancer [...]
In Situ 3D Scaffold-Mediated T-Cell Transduction
Use of three-dimensional (3D) scaffolds in vivo to influence cell behavior is not a new concept. However, recently reported work innovatively applies the approach to the field of cancer immunotherapy1. The use of 3D scaffolds loaded with lentiviral vectors (LVs) to program host T-cells [...]
Live on our YouTube our Latest Webinar: Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance
https://www.youtube.com/watch?v=ACj85aO00hY&t=176s
Natural Killer T (NKT) Cells in Cancer Immunotherapy
While T cells engineered with chimeric antigen receptors (CAR-T cells) have revolutionized the landscape of hematologic malignancy treatment, their efficacy against solid tumors remains limited. However, there is a promising alternative: Natural Killer T (NKT) cells. These innate-like T lymphocytes are unique contenders in [...]